Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

Ofrat Beyar-Katz; Noa Lavi; Shimrit Ringelstein-Harlev; Israel Henig; Dana Yehudai-Ofir; Nuhad Haddad; Riva Fineman; Yishai Ofran; Yuval Nov; Dvora Sahar; Nivin Moustafa-Hawash; Jacob M. Rowe; Tsila Zuckerman

doi:10.1080/10428194.2019.1594214

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

Ofrat Beyar-Katz, Noa Lavi, Shimrit Ringelstein-Harlev, Israel Henig, Dana Yehudai-Ofir, Nuhad Haddad, Riva Fineman, Yishai Ofran, Yuval Nov, Dvora Sahar, Nivin Moustafa-Hawash, Jacob M. Rowe, Tsila Zuckerman

Department of Statistics

Research output: Contribution to journal › Article › peer-review

Abstract

Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.

Original language	English
Pages (from-to)	2449-2456
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	60
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2019.1594214
State	Published - 24 Aug 2019

Bibliographical note

Funding Information:
The research of Yuval Nov was supported in part by the Israeli Science Foundation grant 286/13.

Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

Acute myeloid leukemia (AML)
NPM1 mutation
autologous SCT (ASCT)
core-binding factor (CBF) translocation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2019.1594214

Cite this

Beyar-Katz, O., Lavi, N., Ringelstein-Harlev, S., Henig, I., Yehudai-Ofir, D., Haddad, N., Fineman, R., Ofran, Y., Nov, Y., Sahar, D., Moustafa-Hawash, N., Rowe, J. M., & Zuckerman, T. (2019). Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Leukemia and Lymphoma, 60(10), 2449-2456. https://doi.org/10.1080/10428194.2019.1594214

@article{0e9a8a16c23b40f6b4a9323d4176b10a,

title = "Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation",

abstract = "Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.",

keywords = "Acute myeloid leukemia (AML), NPM1 mutation, autologous SCT (ASCT), core-binding factor (CBF) translocation",

author = "Ofrat Beyar-Katz and Noa Lavi and Shimrit Ringelstein-Harlev and Israel Henig and Dana Yehudai-Ofir and Nuhad Haddad and Riva Fineman and Yishai Ofran and Yuval Nov and Dvora Sahar and Nivin Moustafa-Hawash and Rowe, {Jacob M.} and Tsila Zuckerman",

note = "Funding Information: The research of Yuval Nov was supported in part by the Israeli Science Foundation grant 286/13. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = aug,

day = "24",

doi = "10.1080/10428194.2019.1594214",

language = "English",

volume = "60",

pages = "2449--2456",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

Beyar-Katz, O, Lavi, N, Ringelstein-Harlev, S, Henig, I, Yehudai-Ofir, D, Haddad, N, Fineman, R, Ofran, Y, Nov, Y, Sahar, D, Moustafa-Hawash, N, Rowe, JM & Zuckerman, T 2019, 'Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation', Leukemia and Lymphoma, vol. 60, no. 10, pp. 2449-2456. https://doi.org/10.1080/10428194.2019.1594214

TY - JOUR

T1 - Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

AU - Beyar-Katz, Ofrat

AU - Lavi, Noa

AU - Ringelstein-Harlev, Shimrit

AU - Henig, Israel

AU - Yehudai-Ofir, Dana

AU - Haddad, Nuhad

AU - Fineman, Riva

AU - Ofran, Yishai

AU - Nov, Yuval

AU - Sahar, Dvora

AU - Moustafa-Hawash, Nivin

AU - Rowe, Jacob M.

AU - Zuckerman, Tsila

N1 - Funding Information: The research of Yuval Nov was supported in part by the Israeli Science Foundation grant 286/13. Publisher Copyright: © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/8/24

Y1 - 2019/8/24

N2 - Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.

AB - Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.

KW - Acute myeloid leukemia (AML)

KW - NPM1 mutation

KW - autologous SCT (ASCT)

KW - core-binding factor (CBF) translocation

UR - http://www.scopus.com/inward/record.url?scp=85063911939&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1594214

DO - 10.1080/10428194.2019.1594214

M3 - Article

C2 - 30943060

AN - SCOPUS:85063911939

SN - 1042-8194

VL - 60

SP - 2449

EP - 2456

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this